Endo Pharmaceuticals Holdings News

Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stageA milestone in one of their collaborative programs with , USA-based Endo Pharmaceuticals that has nominated a candidate into full development.

The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012.

Watson Pharmaceuticals Inc. : Leerink says day one of the Lidoderm patent trial produced no surprises, adding it continues to expect Watson Pharmaceuticals to prevail.

A month after licensing a clinical-stage chronic pain treatment to Endo Pharmaceuticals in a deal worth up to $180 million, BioDelivery Sciences International is now preparing an additional $40 million financial cushion.

Endo Pharmaceuticals Holdings Inc. to Announce Fourth Quarter and Full Year 2011 Financial Results on February 24, 2012 Investors and other interested parties may call 800-561-2718 or 617-614-3525 and enter passcode 29896529.

Investors and other interested parties may call 800-561-2718 or 617-614-3525 and enter passcode 29896529.A Please dial in 10 minutes prior to the scheduled start time.

We are maintaining our Neutral stance on Endo Pharmaceuticals with a target price of $39.00. Endo Pharma is a specialty healthcare solutions company that operates in the US and offers more than 175 products in the areas of pain management, urology and oncology.

For investors concerned about the macroeconomy, biotechnology provides some of the safest plays.

Research analysts at Jefferies Group cut their price target on shares of Endo Pharmaceuticals to $48.00 in a report issued on Monday.

TCGLS will receive undisclosed success fees against these milestones. In the first of two fully integrated discovery programs with Endo aimed at identifying novel small molecule drug candidates for an unmet medical need, TCGLS has successfully delivered a pre-clinical development candidate.

Endo Pharmaceuticals 's stock had its "neutral" rating reaffirmed by Zacks Investment Research in a research report issued to clients and investors on Wednesday.

To save time in the future, you may select one of the preferences below. You may update your e IBD preferences at any time by going into My IBD and selecting Update Your e IBD Preferences.

Endo's third-quarter filing with the Securities and Exchange Commission showed an increase in spending on research and development in that quarter compared with the same period in 2010, which could represent a slight difference from the industry trends.

MALVERN, Pa., Jan. 17, 2012 /PRNewswire-USNewswire/ -- Governor Tom Corbett today visited the future site of Endo Pharmaceutical's corporate headquarters in Chester County, where he praised the company for its continued commitment to the region and its plans to create more than 150 high-paying jobs.

The company outgrew its four-building facility in Chadds Ford and will move its 500-some employees, perhaps as early as December of this year, if construction progress allows.

The resolution of the REMS issues for Onsolis, BioDelivery Science's treatment for breakthrough pain in cancer patients, and a money new partnership with Endo Pharmaceuticals to bring BEMA Buprenorphine to market had BDSI trading higher by over 100% earlier this month, but the stock received another huge boost this week when a two-million-share ... (more)

The U.S Food and Drug Administration is cautioning consumers about a potential mix-up between powerful prescription painkillers known as opioids and common over-the-counter drugs made at a Novartis manufacturing plant in Lincoln, Nebraska.